PUBLICATIONS
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2015
Sep 8.
pii: S1470-2045(15)00198-9. doi: 10.1016/S1470-2045(15)00198-9.
Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre ML, Meinhardt G, Llovet JM; STORM investigators.
Lancet Oncol. 2015
Sep 8.
pii: S1470-2045(15)00198-9. doi: 10.1016/S1470-2045(15)00198-9.